Health
New cannabinoid treatments to focus on mental health
New formulations of cannabinoid treatments are being developed to focus on women’s health and mental illness as the pandemic adds pressure to tackle the mental health crisis.
Research company, Spectral Analytics Precision Tele-Monitoring, which focuses on supplementation of the endocannabinoid system, has begun developing new formulations designed to help patients with mental health and women’s health issues.
The new formulations will be developed to help those particularly struggling to overcome PTS, depression, ADHD, bi-polar, endometriosis, immunodeficiency, and weight management.
It comes as the coronavirus pandemic creates a growing demand for mental health awareness and the need for clinical research to develop more effective formulations is greater than ever before.
A recent survey from the Centers for Disease Control (CDC) showed that from June 24-30, 2020, adults in the US reported “considerably elevated adverse mental health conditions associated with COVID-19.”
The CDC survey also found that 40.9 percent of 5,470 respondents reported an adverse mental or behavioral health condition, including symptoms of anxiety disorder or depressive disorder, trauma-related symptoms, new or increased substance use, or thoughts of suicide.
Christina DiArcangelo, CEO of Spectral Analytics Precision Tele-Monitoring commented: “I am so very pleased to announce our focus in mental health and women’s health phytocannabinoid treatments.
“We are shining a light on the fact that this patient population has been forgotten in drug development.”
DiArcangelo added: “In addition, with the negative impacts this pandemic has had on mental health, we feel a responsibility to step up and provide relief.”
Spectral Analytics Precision Tele-Monitoring is a nutraceutical research company with the fundamental premise that phytocannabinoid supplementation of the endocannabinoid system through the use of cannabinoids and other nutraceuticals will improve health.
The company is hoping to have its first round of formulations complete by late spring/summer 2021.
-
Health3 months agoCannabis linked to ‘substantial improvements’ in endometriosis symptoms
-
News4 months agoGrounding of British Airways flight sparks calls for more medical cannabis education
-
Industry4 months agoThe tipping point? UK cannabis clinics urged to clean up ‘concerning’ prescribing practices
-
Industry6 months agoLyphe UK to Launch Noidecs Vital, a New Low-Cost Medical Cannabis Line
-
News5 months agoA new centre-left government and the potential for ‘change’ in the UK cannabis landscape
-
Health6 months agoNew UK study highlights scale of illegal cannabis use for health reasons
-
Science5 months agoCBG found to reduce anxiety and enhance memory in clinical trial
-
Epilepsy2 months ago
UCL Launches 2 Medical Cannabis Trials Into Childhood Epilepsy, but Experts Warn It Is Not the Solution Many Have Been Waiting For
